NDAORALTABLETPriority Review
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Clinical Trials (2)
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Started Dec 2003
3 enrolled
HIV-1 Infection
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
25 enrolled
HIV Infections